- Home
- NUVL vs ZWS Comparison
NUVL vs ZWS Comparison
Compare NUVL & ZWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ZWS
- Stock Information
- Founded
- NUVL 2017
- ZWS 1891
- Country
- NUVL United States
- ZWS United States
- Employees
- NUVL N/A
- ZWS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ZWS Industrial Machinery/Components
- Sector
- NUVL Health Care
- ZWS Industrials
- Exchange
- NUVL Nasdaq
- ZWS Nasdaq
- Market Cap
- NUVL 5.8B
- ZWS 5.9B
- IPO Year
- NUVL 2021
- ZWS 2012
- Fundamental
- Price
- NUVL $77.76
- ZWS $44.97
- Analyst Decision
- NUVL Strong Buy
- ZWS Buy
- Analyst Count
- NUVL 10
- ZWS 6
- Target Price
- NUVL $119.60
- ZWS $39.50
- AVG Volume (30 Days)
- NUVL 482.8K
- ZWS 1.3M
- Earning Date
- NUVL 08-11-2025
- ZWS 07-29-2025
- Dividend Yield
- NUVL N/A
- ZWS 0.80%
- EPS Growth
- NUVL N/A
- ZWS 30.58
- EPS
- NUVL N/A
- ZWS 1.01
- Revenue
- NUVL N/A
- ZWS $1,614,000,000.00
- Revenue This Year
- NUVL N/A
- ZWS $4.31
- Revenue Next Year
- NUVL N/A
- ZWS $4.65
- P/E Ratio
- NUVL N/A
- ZWS $45.45
- Revenue Growth
- NUVL N/A
- ZWS 4.74
- 52 Week Low
- NUVL $55.54
- ZWS $27.74
- 52 Week High
- NUVL $113.51
- ZWS $44.98
- Technical
- Relative Strength Index (RSI)
- NUVL 43.20
- ZWS 83.56
- Support Level
- NUVL $77.41
- ZWS $36.59
- Resistance Level
- NUVL $83.50
- ZWS $37.87
- Average True Range (ATR)
- NUVL 3.08
- ZWS 1.08
- MACD
- NUVL -0.75
- ZWS 0.78
- Stochastic Oscillator
- NUVL 14.84
- ZWS 99.99
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.